Your session is about to expire
← Back to Search
JDQ443 Combinations for Advanced Cancer (KontRASt-03 Trial)
KontRASt-03 Trial Summary
This trialstudies how well new treatments work in people with advanced cancer with a specific gene mutation.
KontRASt-03 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKontRASt-03 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.KontRASt-03 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have advanced colorectal cancer with a specific mutation and have been treated with certain chemotherapies.I have not taken a KRAS G12C inhibitor for my condition.I can have a biopsy based on my hospital's rules.My liver, kidneys, or bone marrow are not working well.I have advanced lung cancer with a specific mutation and have had platinum chemotherapy and immunotherapy.I have active brain cancer spread.I have heart problems or risk factors for heart disease.I am fully active or can carry out light work.My tumor has a specific mutation, but not the KRAS G12C mutation.My cancer is advanced with a KRAS G12C mutation and I've had or can't have standard treatment.
- Group 1: JDQ443+trametinib
- Group 2: JDQ443+ribociclib
- Group 3: JDQ443+cetuximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still room for participants in this research?
"Affirmative. According to the information posted on clinicaltrials.gov, recruitment for this trial is currently underway. Initial postings were made in January of 2022 and a subsequent update was done nine months later in September 2023. The study seeks 346 participants from two different sites."
What is the current cohort size for this research endeavor?
"Affirmative. Clinicaltrials.gov data indicates that this experiment, which was originally published on May 1st 2022, is actively seeking participants. Approximately 346 individuals need to be sourced from two different research sites."
What is the purpose of this clinical research endeavor?
"Novartis Pharmaceuticals, the trial sponsor, states that the primary endpoint of this two year long study is Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) for each treatment regimen. As secondary outcomes, researchers will consider Dose escalation and Phase II Disease Control Rate (DCR) by local review per RECIST 1.1 which measures tumor shrinkage or slowing down as signs of activity; Tmax-Cmax time to achieve maximum plasma drug concentration after single dose administration; and DCR by BIRC per RECIST 1.1 measuring tumor response in a similar fashion."
Share this study with friends
Copy Link
Messenger